5 July 2006
Boxmeer, The Netherlands
Five months after signing an agreement on sale and purchase the Foot-and-Mouth (FMD) vaccine factory in Cologne Bayer HealthCare AG and Intervet International bv have completed the acquisition.
Both parties have agreed not to disclose financial details.
As of July 4, 2006 Intervet, internationally market leader in Animal Health vaccines, is responsible for managing the FMD factory. The site will become Intervet’s international competence centre for FMD vaccine production,
development and research and will serve the needs from the markets for safe and efficacious FMD vaccines. In addition to this, the factory will also engage in antigen banks, which can, under governmental contracts, guarantee
emergency supply of vaccines. By acquiring the Cologne factory Intervet substantially strengthens its worldwide position in the field of Foot-and-Mouth disease vaccines.
Note for the editor
Intervet, a business unit of Akzo Nobel, based in Boxmeer, the Netherlands, with sales of EUR 1,094 million in 2005, is dedicated to research and development, production and marketing of innovative animal health products. Intervet's product range for use in livestock, companion animals, poultry and fish includes vaccines, antiparasitics, anti-infectives, endocrine products and other pharmaceutical specialties. Intervet operates globally with its own marketing organizations. The company currently employs around 5,000 people.
Internet: www.intervet.com
Akzo Nobel is a Global Fortune 500 company and is listed on both the Euronext Amsterdam and NASDAQ stock exchanges. It is also included on the Dow Jones Sustainability Indexes and FTSE4Good Index. Based in the Netherlands, we are a multicultural organization serving customers throughout the world with human and animal healthcare products, coatings, and chemicals. We employ around 61,500 people and conduct our activities in four segments - human and animal health, coatings and chemicals - subdivided into 13 business units, with operating subsidiaries in more than 80 countries. Consolidated revenues for 2005 totaled EUR 13.0 billion. The financial results for the second quarter will be published on July 20, 2006.
Internet: www.akzonobel.com
Sabine Schueller
Communications & Public Affairs
Intervet International bv communications@intervet.com
Tel: +31 (0)485 587085
Fax:+31 (0)485 585392
Press release
Intervet International bv
Wim de Körverstraat 35
P.O. Box 31
5830 AA Boxmeer
Tel. +31 485 58 7600
Fax +31 485 57 7333
www.intervet.com
Akzo Nobel Safe Harbor Statement applies to this press release.
Safe Harbor Statement*
This press release may contain statements which address such key issues as Akzo Nobel’s growth strategy,
future financial results, market positions, product development, pharmaceutical products in the pipeline, and
product approvals. Such statements, including but not limited to the “Outlook”, should be carefully considered
and it should be understood that many factors could cause forecasted and actual results to differ from these
statements. These factors include, but are not limited to, price fluctuations, currency fluctuations,
developments in raw material and personnel costs, pensions, physical and environmental risks, legal issues,
and legislative, fiscal, and other regulatory measures. These factors also include changes in regulations or
interpretations related to the implementation and reporting under IFRS, decisions to apply a different option of
presentation permitted by IFRS, and various other factors related to the implementation of IFRS, including the
implementation of IAS 32 and 39 for financial instruments. Stated competitive positions are based on
management estimates supported by information provided by specialized external agencies. For a more
complete discussion of the risk factors affecting our business please refer to our Annual Report on Form 20-F
filed with the United States Securities and Exchange Commission, a copy of which can be found on the
Company’s website www.akzonobel.com.
• Pursuant to the U.S. Private Securities Litigation Reform Act 1995.
